<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wikimd.com/index.php?action=history&amp;feed=atom&amp;title=Exokernel</id>
	<title>Exokernel - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wikimd.com/index.php?action=history&amp;feed=atom&amp;title=Exokernel"/>
	<link rel="alternate" type="text/html" href="https://wikimd.com/index.php?title=Exokernel&amp;action=history"/>
	<updated>2026-04-04T15:22:59Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.44.2</generator>
	<entry>
		<id>https://wikimd.com/index.php?title=Exokernel&amp;diff=5606614&amp;oldid=prev</id>
		<title>Prab: CSV import</title>
		<link rel="alternate" type="text/html" href="https://wikimd.com/index.php?title=Exokernel&amp;diff=5606614&amp;oldid=prev"/>
		<updated>2024-04-15T13:06:34Z</updated>

		<summary type="html">&lt;p&gt;CSV import&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;[[File:exokernel revised(english).png|thumb]] [[File:The MINIX 3 Microkernel Architecture.png|thumb]] CSL Limited is a global [[biotechnology]] company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL Limited is not directly associated with the concept of an [[Exokernel]], which is a computer science term referring to a streamlined type of [[operating system]] kernel. Therefore, this article will be divided into two sections to address both topics separately.&lt;br /&gt;
&lt;br /&gt;
==CSL Limited==&lt;br /&gt;
[[CSL Limited]] is an Australian multinational [[biotechnology]] company that was founded in 1916 as the Commonwealth Serum Laboratories. It has since grown into a global healthcare leader, specializing in rare diseases, [[vaccines]], [[antivenoms]], and [[blood plasma]] derivatives. CSL&amp;#039;s mission is to save lives and protect the health of people around the world. Its products are essential in the treatment of serious medical conditions such as [[hemophilia]], [[immune deficiencies]], [[hereditary angioedema]], and [[influenza]].&lt;br /&gt;
&lt;br /&gt;
===Operations===&lt;br /&gt;
CSL operates through two main divisions: CSL Behring and Seqirus. CSL Behring focuses on immunoglobulin therapies, [[specialty products]], and [[hereditary angioedema]], while Seqirus is the second-largest [[influenza vaccine]] provider in the world. CSL also operates one of the world&amp;#039;s largest plasma collection networks, CSL Plasma, which is crucial for its plasma-derived therapies.&lt;br /&gt;
&lt;br /&gt;
===Research and Development===&lt;br /&gt;
CSL is committed to innovation and invests heavily in [[research and development]] (R&amp;amp;D) to improve existing therapies and create new treatments. Its R&amp;amp;D efforts are focused on areas of unmet medical need, with a strong pipeline of products in various stages of development.&lt;br /&gt;
&lt;br /&gt;
[[Category:Biotechnology companies]]&lt;br /&gt;
[[Category:Pharmaceutical companies]]&lt;br /&gt;
[[Category:Companies of Australia]]&lt;br /&gt;
&lt;br /&gt;
==Exokernel==&lt;br /&gt;
An [[Exokernel]] is an [[operating system]] architecture that fundamentally differs from conventional monolithic kernel designs by serving as a thin layer between the hardware and application-level software. The main philosophy behind an exokernel is to minimize the responsibilities of the kernel by delegating them to application-level software. This approach allows applications to access hardware resources more directly and efficiently.&lt;br /&gt;
&lt;br /&gt;
===Concept===&lt;br /&gt;
The exokernel architecture aims to provide application-level software with as much freedom as possible, while still ensuring system security and efficiency. It does this by carefully exposing hardware resources to applications, which can then manage these resources with library operating systems (libOSes). This design contrasts with traditional operating systems, which abstract and manage hardware resources through a fixed set of interfaces, often leading to inefficiencies and limitations for specific applications.&lt;br /&gt;
&lt;br /&gt;
===Advantages===&lt;br /&gt;
The exokernel design offers several advantages, including improved performance, flexibility, and security. By allowing applications to directly manage hardware resources, exokernels can reduce overhead and increase execution speed. Additionally, this architecture provides developers with the flexibility to optimize their applications for specific hardware configurations. Security is enhanced by the exokernel&amp;#039;s ability to enforce protection and isolation at a low level, minimizing the risk of system-wide vulnerabilities.&lt;br /&gt;
&lt;br /&gt;
===Challenges===&lt;br /&gt;
Despite its advantages, the exokernel architecture also faces challenges, particularly in terms of compatibility and complexity. Developing applications for exokernels requires a deeper understanding of hardware resources, which can increase the complexity of software development. Additionally, the lack of standardization across exokernels can lead to compatibility issues between different systems and applications.&lt;br /&gt;
&lt;br /&gt;
[[Category:Operating systems]]&lt;br /&gt;
[[Category:Computer architecture]]&lt;br /&gt;
&lt;br /&gt;
{{computer-science-stub}}&lt;/div&gt;</summary>
		<author><name>Prab</name></author>
	</entry>
</feed>